Atyr Pharma Inc. (LIFE) Given a $8.00 Price Target at BMO Capital Markets
Atyr Pharma Inc. (NASDAQ:LIFE) has been assigned a $8.00 price objective by stock analysts at BMO Capital Markets in a report issued on Thursday. The brokerage currently has a a “hold” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 168.46% from the company’s current price.
Several other equities research analysts also recently weighed in on the company. Citigroup Inc. increased their price target on Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, August 16th. JPMorgan Chase & Co. cut their price objective on Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Finally, Zacks Investment Research upgraded Atyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Tuesday, August 16th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $6.50.
Shares of Atyr Pharma (NASDAQ:LIFE) traded down 3.70% during midday trading on Thursday, reaching $2.86. 129,347 shares of the company’s stock traded hands. Atyr Pharma has a 52 week low of $2.48 and a 52 week high of $13.26. The stock’s 50 day moving average is $3.15 and its 200-day moving average is $3.30. The company’s market capitalization is $67.83 million.
Atyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. On average, analysts forecast that Atyr Pharma will post ($2.56) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. A.R.T. Advisors LLC boosted its position in shares of Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock worth $108,000 after buying an additional 18,410 shares in the last quarter. Bridgeway Capital Management Inc. purchased a new position in shares of Atyr Pharma during the second quarter worth $133,000. BlackRock Institutional Trust Company N.A. boosted its position in shares of Atyr Pharma by 317.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 344,214 shares of the company’s stock worth $957,000 after buying an additional 261,753 shares in the last quarter. BlackRock Advisors LLC boosted its position in shares of Atyr Pharma by 14,820.9% in the second quarter. BlackRock Advisors LLC now owns 244,405 shares of the company’s stock worth $679,000 after buying an additional 242,767 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Atyr Pharma by 120.3% in the second quarter. Vanguard Group Inc. now owns 439,732 shares of the company’s stock worth $1,223,000 after buying an additional 240,101 shares in the last quarter. Institutional investors and hedge funds own 44.75% of the company’s stock.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.